PhotoBarr

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
07-05-2012
Summary of Product characteristics Summary of Product characteristics (SPC)
07-05-2012
Public Assessment Report Public Assessment Report (PAR)
07-05-2012

Active ingredient:

натрий porfimer

Available from:

Pinnacle Biologics B.V. 

ATC code:

L01XD01

INN (International Name):

porfimer sodium

Therapeutic group:

Антинеопластични средства

Therapeutic area:

Хранопровод На Барет

Therapeutic indications:

Фотодинамична терапия (ФДТ) с PhotoBarr е предназначен за: премахване на тежка дисплазия (ГГД) при пациенти с хранопровода на Барет (БО).

Product summary:

Revision: 9

Authorization status:

Отменено

Authorization date:

2004-03-25

Patient Information leaflet

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
IME ZDRAVILA
PhotoBarr 15 mg prašek za raztopino za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
_ _
Ena viala
vsebuje 15 mg porfimer-natrija. Po pripravi vsebuje vsak ml raztopine
2,5 mg
porfimer-natrija.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Prašek za raztopino za injiciranje.
Temno rdeč do rdečkastorjav liofiliziran prašek ali pogača.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Fotodinamično zdravljenje (PDT, photodynamic therapy) s PhotoBarrom
je indicirano v primeru
odprave displazije visoke stopnje (HGD, high-grade dysplasia) pri
bolnikih z Barrettovim
požiralnikom (BP).
4.2
ODMERJANJE IN NAČIN UPORABE
Fotodinamično zdravljenje s PhotoBarrom mora opraviti zdravnik, ki
ima izkušnje z endoskopskimi
laserskimi postopki oz. se lahko opravi le pod nadzorom takega
zdravnika. Zdravilo dajemo le takrat,
ko je na voljo material in osebje, izkušeno v ocenjevanju in
zdravljenju anafilaksije.
Odmerjanje
Priporočeni odmerek PhotoBarra je 2 mg/kg telesne mase.
Rekonstituirana raztopina PhotoBarra (ml) = bolnikova masa (kg) x 2
mg/kg = 0,8 x bolnikova masa
2,5 mg/ml
Po pripravi je PhotoBar temno rdeča do rdečkastorjava motna
raztopina.
Uporabiti je dovoljeno le raztopino brez delcev in brez vidnih znakov
kvarjenja.
Fotodinamično zdravljenje s PhotoBarrom je dvostopenjski proces, ki
zahteva uporabo tako zravila kot
svetlobe. En ciklus PDT se sestoji iz enega injiciranja PhotoBarra ter
ene ali dveh aplikacij svetlobe.
V primeru trdovratne HGD je možno nadaljnje zdravljenje
(do največ treh
ciklusov) (v razmaku
najmanj 90 dni), da se poveča odstotek odzivov. To je treba
pretehtati glede na povečano stopnjo
nastanka strikture (glejte poglavje 4.8 ter poglavje 5.1).
Razvoj raka je bil povezan s številom opravljenih ciklusov PDT. Pri
bolnikih, ki so prejeli samo eno
epizodo PDT, je bilo tveganje razvoja 
                                
                                Read the complete document

Summary of Product characteristics

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
IME ZDRAVILA
PhotoBarr 15 mg prašek za raztopino za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
_ _
Ena viala
vsebuje 15 mg porfimer-natrija. Po pripravi vsebuje vsak ml raztopine
2,5 mg
porfimer-natrija.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Prašek za raztopino za injiciranje.
Temno rdeč do rdečkastorjav liofiliziran prašek ali pogača.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Fotodinamično zdravljenje (PDT, photodynamic therapy) s PhotoBarrom
je indicirano v primeru
odprave displazije visoke stopnje (HGD, high-grade dysplasia) pri
bolnikih z Barrettovim
požiralnikom (BP).
4.2
ODMERJANJE IN NAČIN UPORABE
Fotodinamično zdravljenje s PhotoBarrom mora opraviti zdravnik, ki
ima izkušnje z endoskopskimi
laserskimi postopki oz. se lahko opravi le pod nadzorom takega
zdravnika. Zdravilo dajemo le takrat,
ko je na voljo material in osebje, izkušeno v ocenjevanju in
zdravljenju anafilaksije.
Odmerjanje
Priporočeni odmerek PhotoBarra je 2 mg/kg telesne mase.
Rekonstituirana raztopina PhotoBarra (ml) = bolnikova masa (kg) x 2
mg/kg = 0,8 x bolnikova masa
2,5 mg/ml
Po pripravi je PhotoBar temno rdeča do rdečkastorjava motna
raztopina.
Uporabiti je dovoljeno le raztopino brez delcev in brez vidnih znakov
kvarjenja.
Fotodinamično zdravljenje s PhotoBarrom je dvostopenjski proces, ki
zahteva uporabo tako zravila kot
svetlobe. En ciklus PDT se sestoji iz enega injiciranja PhotoBarra ter
ene ali dveh aplikacij svetlobe.
V primeru trdovratne HGD je možno nadaljnje zdravljenje
(do največ treh
ciklusov) (v razmaku
najmanj 90 dni), da se poveča odstotek odzivov. To je treba
pretehtati glede na povečano stopnjo
nastanka strikture (glejte poglavje 4.8 ter poglavje 5.1).
Razvoj raka je bil povezan s številom opravljenih ciklusov PDT. Pri
bolnikih, ki so prejeli samo eno
epizodo PDT, je bilo tveganje razvoja 
                                
                                Read the complete document

Similar products

Active ingredient натрий porfimer

натрий porfimer

ATC code L01XD01

L01XD01

Marketed by Pinnacle Biologics B.V. 

Pinnacle Biologics B.V. 

INN (International Name) porfimer sodium

porfimer sodium

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 07-05-2012
Summary of Product characteristics Summary of Product characteristics Spanish 07-05-2012
Public Assessment Report Public Assessment Report Spanish 07-05-2012
Patient Information leaflet Patient Information leaflet Czech 07-05-2012
Summary of Product characteristics Summary of Product characteristics Czech 07-05-2012
Public Assessment Report Public Assessment Report Czech 07-05-2012
Patient Information leaflet Patient Information leaflet Danish 07-05-2012
Summary of Product characteristics Summary of Product characteristics Danish 07-05-2012
Public Assessment Report Public Assessment Report Danish 07-05-2012
Patient Information leaflet Patient Information leaflet German 07-05-2012
Summary of Product characteristics Summary of Product characteristics German 07-05-2012
Public Assessment Report Public Assessment Report German 07-05-2012
Patient Information leaflet Patient Information leaflet Estonian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Estonian 07-05-2012
Public Assessment Report Public Assessment Report Estonian 07-05-2012
Patient Information leaflet Patient Information leaflet Greek 07-05-2012
Summary of Product characteristics Summary of Product characteristics Greek 07-05-2012
Public Assessment Report Public Assessment Report Greek 07-05-2012
Patient Information leaflet Patient Information leaflet English 07-05-2012
Summary of Product characteristics Summary of Product characteristics English 07-05-2012
Public Assessment Report Public Assessment Report English 07-05-2012
Patient Information leaflet Patient Information leaflet French 07-05-2012
Summary of Product characteristics Summary of Product characteristics French 07-05-2012
Public Assessment Report Public Assessment Report French 07-05-2012
Patient Information leaflet Patient Information leaflet Italian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Italian 07-05-2012
Public Assessment Report Public Assessment Report Italian 07-05-2012
Patient Information leaflet Patient Information leaflet Latvian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Latvian 07-05-2012
Public Assessment Report Public Assessment Report Latvian 07-05-2012
Patient Information leaflet Patient Information leaflet Lithuanian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-05-2012
Public Assessment Report Public Assessment Report Lithuanian 07-05-2012
Patient Information leaflet Patient Information leaflet Hungarian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Hungarian 07-05-2012
Public Assessment Report Public Assessment Report Hungarian 07-05-2012
Patient Information leaflet Patient Information leaflet Maltese 07-05-2012
Summary of Product characteristics Summary of Product characteristics Maltese 07-05-2012
Public Assessment Report Public Assessment Report Maltese 07-05-2012
Patient Information leaflet Patient Information leaflet Dutch 07-05-2012
Summary of Product characteristics Summary of Product characteristics Dutch 07-05-2012
Public Assessment Report Public Assessment Report Dutch 07-05-2012
Patient Information leaflet Patient Information leaflet Polish 07-05-2012
Summary of Product characteristics Summary of Product characteristics Polish 07-05-2012
Public Assessment Report Public Assessment Report Polish 07-05-2012
Patient Information leaflet Patient Information leaflet Portuguese 07-05-2012
Summary of Product characteristics Summary of Product characteristics Portuguese 07-05-2012
Public Assessment Report Public Assessment Report Portuguese 07-05-2012
Patient Information leaflet Patient Information leaflet Romanian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Romanian 07-05-2012
Public Assessment Report Public Assessment Report Romanian 07-05-2012
Patient Information leaflet Patient Information leaflet Slovak 07-05-2012
Summary of Product characteristics Summary of Product characteristics Slovak 07-05-2012
Public Assessment Report Public Assessment Report Slovak 07-05-2012
Patient Information leaflet Patient Information leaflet Slovenian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Slovenian 07-05-2012
Public Assessment Report Public Assessment Report Slovenian 07-05-2012
Patient Information leaflet Patient Information leaflet Finnish 07-05-2012
Summary of Product characteristics Summary of Product characteristics Finnish 07-05-2012
Public Assessment Report Public Assessment Report Finnish 07-05-2012
Patient Information leaflet Patient Information leaflet Swedish 07-05-2012
Summary of Product characteristics Summary of Product characteristics Swedish 07-05-2012
Public Assessment Report Public Assessment Report Swedish 07-05-2012
Patient Information leaflet Patient Information leaflet Norwegian 07-05-2012
Summary of Product characteristics Summary of Product characteristics Norwegian 07-05-2012
Patient Information leaflet Patient Information leaflet Icelandic 07-05-2012
Summary of Product characteristics Summary of Product characteristics Icelandic 07-05-2012

Search alerts related to this product

Alerts PhotoBarr натрий porfimer sodium

PhotoBarr натрий porfimer sodium

View documents history

Documents history Documents history

PhotoBarr